<DOC>
	<DOCNO>NCT02620280</DOCNO>
	<brief_summary>This study aim evaluate addition MPDL3280A ( atezolizumab ) carboplatin nab-paclitaxel patient locally advanced triple negative breast cancer . compare control arm carboplatin abraxane . Half participant receive MPDL3280A combination carboplatin abraxane , half receive carboplatin abraxane .</brief_summary>
	<brief_title>Neoadjuvant Therapy TRIPle Negative Breast Cancer With antiPDL1</brief_title>
	<detailed_description>Emerging evidence show many breast cancer triple negative basal like feature infiltration mononuclear cell lymphocytes . Irrespective entity tumor infiltration mononuclear cell , expression immune regulatory checkpoint PD-1 ligand B7-H1 ( PD-L1 ) negatively affect result treatment . These data suggest subset patient ongoing immune response within tumor micro-environment , PD-L1 expression adaptive method tumor resistance tumor infiltrate lymphocyte , turn need response chemotherapy . Overall , data suggests role immune regulation response chemotherapy , support concept blockade immune check-points may favor achievement durable response immune mechanism , combination classical chemotherapy . MPDL3280A ( atezolizumab ) human monoclonal antibody contain engineer Fc-domain optimize efficacy safety target PD-L1 block bind receptor , include PD-1 B7.1 . Based consideration , plan conduct study combination abraxane carboplatin without PDL1-directed antibody woman locally advance breast cancer suitable neoadjuvant therapy aim improve event-free survival</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Female patient age 18 year old locally advanced inflammatory breast cancer 2 . Histologically confirm unilateral breast cancer invasive ductal histology otherwise specify ( NOS ) high proliferation grade 3 . HER2 negative disease 4 . Negative estrogen receptor ( ER ) progesterone receptor ( PgR ) , &lt; 1 % locally assess 5 . Representative paraffinembedded ( FFPE ) tumor block take diagnostic biopsy confirmation HER2 , ER PgR eligibility , assessment PDL1 expression exploratory biomarker evaluation mandatory 6 . ECOG performance status 0 1 7 . Written inform consent participate trial ( approved Institutional Review Board [ IRB ] / Independent Ethics Committee [ IEC ] ) obtain prior study specific screen procedure 8 . Willing able comply protocol 9 . Consent collection blood sample 10 . For woman postmenopausal ( ≥ 12 month nontherapyinduced amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement remain abstinent use single combine contraceptive method result failure rate &lt; 1 % per year treatment period least 90 day last dose study drug . 1 . Evidence bilateral breast cancer metastatic disease ( M1 ) 2 . Cases histology different invasive ductal NOS high proliferation grade 3 . Patients HER2positive disease accord ASCO/CAP guideline 2013 4 . Pregnant lactating woman . Documentation negative pregnancy test must available premenopausal woman intact reproductive organ woman less one year last menstrual cycle 5 . Previous treatment chemotherapy , hormonal therapy investigational drug type malignancy 6 . Previous investigational treatment condition within 4 week randomization date 7 . Administration live , attenuated vaccine within 4 week cycle 1 Day 1 anticipation live attenuated vaccine require study 8 . Previous concomitant invasive malignancy type previous invasive breast cancer . Patients curatively treat basal cell carcinoma skin situ cervix cancer generally eligible 9 . Preexisting motor sensory neuropathy grade &gt; 1 reason 10 . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion proteins 11 . Known hypersensitivity allergy biopharmaceuticals produce Chinese hamster ovary cell component MPDL3280A formulation 12 . Patients prior allogeneic stem cell solid organ transplantation 13 . History autoimmune disease include , limited , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , Bell 's palsy , GuillainBarré syndrome , multiple sclerosis , vasculitis , glomerulonephritis 14 . History idiopathic pulmonary fibrosis ( include bronchiolitis obliterans organize pneumonia ) evidence active pneumonitis screen chest compute tomography scan 15 . Known clinically significant liver disease , include active viral , alcoholic , hepatitis , cirrhosis , fatty liver , inherit liver disease 16 . History HIV infection , active hepatitis B ( chronic acute ) , hepatitis C infection . Patients past resolve hepatitis B infection ( define negative HBsAg test positive hepatitis B core antigen [ antiHBc ] test ) eligible . Patients positive hepatitis C virus ( HCV ) antibody eligible polymerase chain reaction assay ( PCR ) negative HCV RNA 17 . Active tuberculosis 18 . Severe infection within 4 week prior cycle 1 Day 1 , include , limited , hospitalization complication infection , bacteremia , severe pneumonia . Signs symptoms significant infection within 2 week prior cycle 1 Day 1 19 . Received oral IV antibiotic within 2 week prior Cycle 1 Day 1 20 . Other serious illness medical condition include : history document congestive cardiac failure ; New York Heart Association ( NYHA ) Class II great CHF ; angina pectoris require antianginal medication unstable angina within 6 month prior cycle 1 Day 1 ; evidence transmural infarction ECG ; myocardial infarction stroke transient ischemic attack ( TIA ) within 6 month prior cycle 1 Day 1 ; poorly control hypertension ( e.g . systolic &gt; 180 mm Hg diastolic &gt; 100 mm Hg ; however , patient hypertension well control medication eligible ) ; clinically significant valvular heart disease ; highrisk uncontrolled arrhythmias 21 . Patients history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant precluding inform consent adversely affect compliance study drug 22 . Serious uncontrolled infection ( bacterial viral ) poorly control diabetes mellitus 23 . Abnormal baseline hematological value 24 . Abnormal baseline laboratory test serum total bilirubin , liver function test , alkaline phosphatase , serum creatinine , INR aPTT 25 . Baseline leave ventricular ejection fraction ( LVEF ) &lt; 50 % echocardiography multigated scintigraphic scan ( MUGA ) 26 . Major surgical procedure within 28 day prior cycle 1 Day 1 anticipation need major surgical procedure course study 27 . Influenza vaccination give influenza season ( approximately October March ) . Patients must receive live , attenuate influenza vaccine ( e.g. , FluMist® ) within 4 week prior cycle 1 Day 1 time study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Triple Negative Breast Cancer</keyword>
</DOC>